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Abstract
Vascular endothelial growth factor (VEGF) plays an important role in Kaposi’s sarcoma (KS). We 
administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-
related KS. Seventeen participants received three different doses of PTC299. Adverse events 
typically observed with VEGF-inhibition were absent. Three participants had partial tumor 
responses and 11 had stable disease. There were no differences in exposure to PTC299 by 
antiretroviral regimen. Serum VEGF, but not KSHV DNA, decreased on treatment. Given 
redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with 
agents that inhibit different pathways implicated in KS and KSHV proliferation.
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INTRODUCTION
Although Kaposi’s sarcoma (KS), the most common AIDS-defining malignancy worldwide 
[1, 2], can be treated with antiretroviral therapy (ART) alone or with chemotherapy added 
[3-5], responses are often incomplete. Cytotoxic chemotherapy may induce acute and 
chronic adverse events and pharmacokinetic interactions with ART, and access to 
chemotherapy is limited in high-incidence, low-resource regions, especially sub-Saharan 
Africa [6, 7]. Thus, alternative treatments are needed.
Vascular endothelial growth factor (VEGF) is highly over-expressed in KS tumors and 
enhances KS-associated herpesvirus (KSHV) entry and KS gene expression within target 
cells [8, 9]. In laboratory studies, inhibiting VEGF expression or its signaling pathways 
results in tumor growth inhibition [10-14]. KSHV-encoded proteins promote vascular 
endothelial reprogramming and immortalization through up-regulation of VEGF and VEGF 
receptors (VEGFr) [15, 16]. Additionally, tumor hypoxia induces p53-mediated apoptosis 
and HIF-1α, further promoting VEGF production [17]. HIF-1α and hypoxemic responses 
are additionally modulated directly by KSHV, and hypoxia further promotes lytic KSHV 
replication [18-21].
PTC299 (PTC Therapeutics Inc, South Plainfield, NJ) an orally-bioavailable VEGF 
inhibitor, acts via post-transcriptional regulation of VEGF mRNA under conditions of 
cellular stress. Transcriptional regulation of VEGF in normal endothelial cells occurs mainly 
through cap-dependent translation of its mRNA. In contrast, cellular stress and hypoxemia 
augment transcription of VEGF in a cap-independent fashion [22-24]. Because PTC299 
targets cap-independent pathways of mRNA translation that predominate during stress such 
as hypoxia and oncogenic transformation, VEGF production in normal endothelium is 
spared, potentially avoiding undesirable off-target effects of generalized VEGF blockade 
observed with other VEGF and VEGFr tyrosine kinase inhibitors (TKIs). PTC299 activity 
was demonstrated in a variety of tumor cell lines and mouse xenograft-tumor models and 
was safe and well tolerated in several phase I clinical trials [25-28].
These considerations led the AIDS Malignancy Consortium (AMC) to evaluate the safety, 
dosing, antitumor activity, and pharmacokinetics of PTC299 in patients with HIV-associated 
KS, and to describe its effects on VEGF expression and KSHV replication.
METHODS
Study Population
Eligible participants were HIV-infected adults with biopsy-proven KS not requiring urgent 
systemic chemotherapy for symptomatic visceral disease. Participants receiving ART were 
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required to be on a stable regimen ≥ 12 weeks without improvement in KS during that time, 
not pregnant or breastfeeding, and to have received no KS treatment within one month. 
Exclusions included Karnofsky score <60, life expectancy <3 months, history of bleeding or 
clotting diathesis, severe hepatic or renal dysfunction, or other active serious medical 
conditions.
After providing informed consent, three participants were sequentially enrolled into each of 
three oral dosage levels, 40mg twice daily (BID), 80mg BID, and 100mg BID, once the 
preceding dose had been administered without dose limiting toxicities (DLT) for one cycle. 
Eight additional participants then received 100mg BID. PTC299 was supplied as 20mg 
capsules. A plan to estimate the maximum tolerated dosage (MTD) was not performed 
because the sponsor suspended enrollment due to change in drug formulation. Each drug 
cycle lasted 28 days. KS response was assessed every 28 days as previously described [29, 
30], and categorized as complete (CR), partial (PR), stable (SD) or progression (PD). 
Participants were considered evaluable for response if they completed 1 cycle of PTC299. 
Participants without CR or PR were removed from study after 6 cycles; treatment was 
likewise discontinued if KS progressed on therapy or DLT occurred. Participants were 
continued on therapy for an additional 2 cycles following CR, or up to 12 cycles for PR.
Laboratory Methods
Biopsies of non-indicator KS lesions were performed at baseline and during week 4, cycle 1, 
and evaluated for changes in expression of viral, angiogenesis and proliferation markers (see 
Supplemental Material).
KSHV DNA was quantified in plasma at baseline, cycles 2 and 5, and treatment 
discontinuation, using competitive DNA PCR [31]. Whole blood CD4+ T cell counts and 
plasma HIV RNA levels were determined at these same time points.
VEGF-A and IL-6 levels were quantified by ELISA (Quest Laboratories, San Juan 
Capistrano, CA) in serum and plasma on Day 1 of cycles 1-6, on Cycle 1, Day 15 and at 
treatment discontinuation.
Serial blood samples for pharmacokinetic analysis were collected immediately preceding 
and at 1, 2, 3, 4, 5, 6, and 8 hours following the morning administration of PTC299 on Cycle 
1, Days 1 and 28. Additional trough samples were obtained on Cycle 1, Day 15 and Cycle 2, 
Day 28. Samples were analyzed and pharmacokinetic parameters estimated as described (see 
Supplemental Material).
Statistical Considerations
Descriptive statistics were used to summarize adverse events and response rates.
Effects of PTC299 on serum and plasma VEGF, VEGFR and cytokine profiles were 
evaluated comparing pre-treatment values with Day 28 and with the lowest value subsequent 
to Day 28, and differences tested with Wilcoxon signed rank tests. Methods for analyzing 
other correlative laboratory endpoints are described in Supplemental Materials.
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RESULTS
Seventeen volunteers were enrolled: 3 at 40 mg BID, 3 at 80 mg BID and 11 at 100 mg BID. 
Baseline characteristics, including extent of KS, ART regimen, HIV parameters, and prior 
KS therapy are described in Table 1, as are details of study treatment.
Five participants completed therapy per protocol, 6 terminated study treatment for KS 
progression, and 4 voluntarily withdrew after a median of 3 cycles. One patient died and one 
withdrew from study before the first response evaluation. PR was documented in 3 
participants (18%), lasting for 2, 3, and 4 months respectively at doses of 40mg BID (n=1) 
and 100mg BID (n=2). Eleven participants showed SD lasting a median of 3 months (IQR 
2-6.5). PD ultimately occurred in 6 participants, of whom 5 initially had either PR or SD.
Safety Assessment
Common adverse events included nausea (41%), vomiting (18%), diarrhea (24%), limb pain 
(47%), and fatigue (29%); >90% of events were Grade 1 or 2. Limb pain, fatigue, and 
peripheral edema were prevalent at baseline and consistent with the primary disease. 
Hyperglycemia (29%), dyslipidemia (53%), elevated creatinine (18%), and proteinuria 
(18%), were the most frequent laboratory abnormalities. Three participants (18%), all 
receiving atazanavir, had elevated bilirubin. All participants with elevated creatinine and/or 
proteinuria received concurrent tenofovir. Serious adverse events were reported in 3 
participants: one grade 3 nephrolithiasis, considered unlikely related to study drug; one 
grade 3 myalgia at the 100 mg/dose level, considered probably PTC299-related; and one 
death. The death was officially ascribed to hypertensive cardiovascular disease and reported 
as possibly study drug-related, although autopsy revealed detectable serum levels of several 
illicit and prescription opiates and sedatives; precise cause of death is therefore uncertain.
Pharmacokinetics
Pharmacokinetics—Pharmacokinetic analysis was available for 15 patients. A post-hoc 
analysis categorizing participants on whether the ART regimen was known to induce 
CYP2C19 (ritonavir) or inhibit CYP2C19 (efavirenz) [32] showed no statistically significant 
alterations in pharmacokinetics of the parent compound, but significant alterations in 
exposure to the less-active metabolite, des-methyl PTC299 (see Supplemental Material)[33]. 
There was no correlation between treatment response and PTC-299 or metabolite exposure 
(p > 0.05)
Effects of PTC299 on Biologic markers
Day 1, cycle 1 levels of serum VEGF were significantly higher than levels at all later time-
points (Figure 1); plasma VEGF showed a less sustained decrease that was significant only 
at intermediate time-points. No changes were observed in serum or plasma IL-6.
There were no significant treatment-associated changes in KSHV viral loads, absolute and 
percent CD4, or immunohistochemical expression of VEGF, VEGFr, phospho-Akt, p53, 
HIF-1α, or Ki-67, or viral gene expression or cellular gene transcription in tumor biopsies.
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DISCUSSION
Recognition of the essential role of VEGF in KS development has prompted evaluation of 
several VEGF inhibitors in AIDS-associated KS. This study evaluated PTC299, a novel, 
orally-bioavailable small molecule that inhibits VEGF protein production by preventing 
translation of pathological VEGF. Because the study was halted early, we were unable to 
define the MTD in this population, but doses administered were similar to those tested in 
other Phase I and II studies. Those trials and ours demonstrated a pharmacokinetic profile 
for PTC299 consistent with maintenance of drug levels well above those required for 
efficacy in preclinical models.
Participants were allocated to PTC299 dosage levels without respect to the concurrent 
antiretroviral regimen. We observed no significant variation between participants receiving 
CYP2C19 inducers and inhibitors in the pharmacokinetics of the parent drug, nor correlation 
of treatment response with drug and metabolite exposure, although metabolite exposure and 
metabolite:parent drug ratio differed significantly between these two groups. Without 
stratified dosage assignments, such as those used in a subsequent AMC trial of sunitinib 
[34], we were unable to correlate adverse events by ART regimen effects on CYP2C19.
We did not observe many of the medically significant side effects of VEGF inhibitors and 
TKIs, such as bleeding, hypertension and renal vascular injury [35, 36]. Mild proteinuria 
was limited to persons receiving tenofovir and/or atazanavir, both known to cause renal 
tubulopathies [37] and all persons with elevated bilirubin levels were receiving atazanivir 
[38]. Fewer adverse events were observed than for other classes of VEGF inhibitors/TKIs, 
suggesting that drugs inhibiting VEGF by targeting tumor-specific mRNA rather than 
general kinase activity may be less likely to induce off-target effects. The short duration of 
PTC299 administration in some participants may, however, have precluded observation of 
potential adverse events.
Although we could not evaluate the planned dosage range of PTC299, moderate serum 
VEGF inhibition was achieved, though only modest effects on KS growth, consistent with 
results from other VEGF inhibitors. Many participants had previously received multiple KS 
treatments, but we did not note a pattern of response with respect to prior receipt of agents 
with anti-VEGF activity. Other studies of VEGF inhibitors in KS reported a 30% response 
rate for bevacizumab, 20% for sorafenib, and no better than SD for sunitunib [34, 39-41]. As 
such, this study highlights a persistent question in the search for improved therapies for KS 
and many soft tissue sarcomas (STS) which similarly over-express VEGF and its receptors 
[42]. It is unclear why, despite the apparent reliance of many such tumors on VEGF 
overproduction, VEGF inhibitors have not proven highly efficacious in these tumors. Five 
VEGF inhibitors have been studied in other STS, of which four received approval for this 
indication. However, single-agent PR rates were only 14% for sorafenib [43], 17% for 
bevacizumab [44], 6% for pazopanib [45] and metabolic PR in 47% of patients receiving 
sunitinib for varied STS [46]. Despite PTC299 activity in multiple pre-clinical in vivo 
sarcoma models [33], and a statistically significant decrease in serum VEGF levels in this 
trial, the response rate of 20% was similar to rates for other TKIs, but inferior to standard-of-
care chemotherapy.
BENDER IGNACIO et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
One reason that single-point blockade of the VEGF pathway may be insufficient to cause 
tumor regression, particularly in AIDS-related KS, is redundancy in the human VEGF 
pathway, which KSHV reinforces at several points [40]. Additionally, while VEGF is 
necessary for proliferation, it may not be necessary for tumor survival. This is similar to the 
mTOR pathway, an upstream regulator of VEGF and IL-6 expression [47-50]. Viral IL-6 and 
KSHV-mediated up-regulation of HIF-1α and VEGFrs may reinforce this autocrine-
paracrine loop, such that single-point blockade of the VEGF pathway is easily circumvented. 
Virus-tumor interactions, allowing up-regulation of alternate pathways, may explain why 
objective responses to single agent VEGF inhibitors have been modest. Lastly, since 
pharmacologic growth factor depletion is seldom complete, the typical outcome of single-
agent therapy in pre-clinical studies is growth arrest, translating to no better than SD in most 
patients.
Given the limited therapeutic results of VEGF monotherapy, a logical next step may be to 
combine mechanistically-distinct VEGF inhibitors [51] or VEGF inhibitors with agents that 
target either tumor or virus. A current example is an ongoing trial of bevacizumab with 
liposomal doxorubicin (NCT00923936). Additionally, nucleoside analog inhibitors of viral 
DNA polymerase with direct gamma herpesvirus activity, despite little anti-KS efficacy as 
single agents [52, 53], may provide adjuvant effects against virally-mediated paracrine 
stimulation to remove redundancy in the VEGF pathway. Furthermore, several HIV protease 
inhibitors have off-target effects on pathways regulating tumor growth, including Akt, NF-
κB, and the 20S proteasome [54, 55]. Of particular interest is nelfinavir, which down-
regulates HIF-1α and VEGF, and has direct anti-herpesvirus activity [56, 57].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Change in mean serum and plasma VEGF levels during treatment with PTC299
Figure legend: This graph demonstrates mean VEGF levels in serum (open boxes) and 
plasma (closed boxes) with standard deviations denoted by brackets. Compared with the 
baseline (C1D1) mean level of 518.1 pg/ml, serum VEGF decreased significantly at all 
subsequent time points ( to 316.9 pg/ml, p=0.001 at C1D15; and to 261.81 pg/ml, p=0.026 at 
the final time point: C5D1). Baseline (C1D1) mean plasma VEGF was 170.4 pg/ml and was 
126.7 pg/ml at C1D15 (p=0.061). Plasma VEGF decreased significantly between baseline 
and C3D1 (120.3 pg/ml, p=0.009) and C4D1 only (72.3 pg/ml,p=0.001) and but not at the 
final time point on C5D1 (109.9 pg/ml, p=0.432).
Abbreviations: VEGF, vascular endothelial growth factor; CxDx, cycle and day of PTC299 
therapy
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Table 1
Baseline Participant Characteristics and Study Therapy Received
Characteristic N=17
Age   median (range) 45 (31,57)
Male 17 (100%)
Race/Ethnicity
  White, non-Hispanic 8 (47)
  Black 4 (24)
  Hispanic 3 (18)
  Asian/Pacific Islander/Other 2 (12)
KS Disease Characteristics
  Oral lesions 1 (6)
  ≥50 lesions 16 (88)
  Tumor-associated edema 16 (88)
Prior treatment for KS* 16 (94)
  Cytotoxic Chemotherapy 14 (82)
  Local therapies (topical, radiation, or cryotherapy) 4 (24)
  Imatinib 4 (24)
  Other/experimental therapies 6 (35)
Baseline KSHV Plasma Log-copies/ml, median (IQR) 4.8 (2.5, 5.8)
CD4 T-cell Count, median (range) 489 (133, 1132)
HIV Viral load undetectable 13 (76)
Current Antiretroviral regimens N =17 (%)
  Nucleoside Analog Backbone
    ABC/d4T 1 (6)
    ABC/3TC/ddI 1 (6)
    TDF/FTC or TDF/3TC 12 (71)
    3TC 1 (6)
    AZT/3TC 1 (6)
    Nucleoside-sparing regimen 1 (6)
  Non-Nucleoside Agents 6 (35)
    EFV 6 (35)
    Protease Inhibitors** 10 (59)
    Other Classes (raltegravir, maraviroc) 5 (29)
PTC299 Cycles Received 40mg BID 80mg BID 100mg BID Total
N=3 N=3 N=11 N=17
      median (range) 7 (6,13) 3 (2,5) 4 (1,10) 5 (1,13)
Abbreviations: KS, Kaposi sarcoma; HIV, human immunodeficiency virus; KSHV, Kaposi Sarcoma-associated herpes virus; IQR, interquartile 
range; ABC, abacavir; d4T, stavudine; 3TC, lamivudine; ddI, didanosine; TDF, tenofovir; FTC, emtricitabine; AZT, zidovodine; EFV, efavirenz.
*
Prior treatments included (# of participants): cytotoxic therapies: liposomal doxorubicin (14), paclitaxel (7), vinblastine (1), etoposide (1), 
vincristine (1), daunomycin (1); Other/experimental therapies included: valproic acid (2), IM-862 (2), rapamycin (1), flavopiridol (1), Col-3 
[incyclinide] (3), interferon-alpha (1), VEGF-antisense (1).
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**
Protease inhibitors included were lopinivir/ritonavir, darunavir/ritonavir, and atazanavir with and without ritonavir.
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